WASHINGTON, Dec. 8 (UPI) -- The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.
The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.
The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.
"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.
Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.
The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.
|Additional Business News Stories|
LONDON, June 19 (UPI) --An oil company working in northern Iraq said Wednesday it was looking to confirm the region may be one of the best in the world in terms of resource potential.
PARIS, June 19 (UPI) --Aerospace industry contracts for commercial aircraft, related systems and services worth billions of dollars are being reported from the Paris Air Show.